Understanding the science behind SPF is essential for effective patient counselling on photoprotection. While sunscreen is widely recognised as a cornerstone of skin cancer prevention, its role extends far beyond UVB protection. Ultraviolet (UV) radiation contributes to photoageing, pigmentation disorders and carcinogenesis through distinct but overlapping biological mechanisms.
Despite the widespread use of SPF ratings, many clinicians and patients misunderstand what these values actually measure and how they translate into real-world protection. This article explores the evidence behind sunscreen efficacy, formulation science, clinical benefits and practical considerations for optimising photoprotection in everyday practice.
UV radiation
Ultraviolet (UV) radiation is a component of solar electromagnetic radiation that reaches the earth’s surface primarily as UVA (320–400 nm) and UVB (280–320 nm). These wavelengths differ in both biological effects and clinical relevance. UVA penetrates more deeply into the dermis and is strongly implicated in photoageing, pigmentary disorders and cumulative structural damage. ¹ ²
UVB is more energetic, largely absorbed within the epidermis, and is the principal driver of erythema and a major contributor to photocarcinogenesis. Both UVA and UVB induce DNA damage, oxidative stress and immunomodulation, underpinning their role in both skin ageing and malignancy.¹ ² Although DNA absorbs approximately four times less UVA than UVB radiation, which leads to less formation of DNA photodamage and subsequent mutations. 3
The Sun Protection Factor (SPF) is the most widely recognised measure of sunscreen efficacy, but it is often misunderstood. SPF quantifies protection against UVB-induced erythema and is calculated as the ratio of the UV dose required to produce minimal erythema on sunscreen-protected skin compared with unprotected skin under standardised in vivo conditions.4
Importantly, SPF does not directly measure UVA protection. As UVA contributes significantly to photoageing and pigmentation, the use of broad-spectrum sunscreens that provide both UVB and UVA protection is essential for comprehensive photoprotection.¹
Benefits of SPF product use
The clinical value of sunscreen is supported by robust evidence. In a landmark randomised controlled trial conducted in Australia, daily application of sunscreen resulted in a 24% reduction in skin ageing progression over 4.5 years compared with discretionary use, while β-carotene supplementation showed no overall benefit.5 This study remains one of the strongest pieces of evidence demonstrating that sunscreen is not merely preventative for cancer, but also an effective anti-ageing intervention. Furthermore, long-term sunscreen use has been associated with reduced incidence of both squamous cell carcinoma and melanoma, reinforcing its role in primary prevention.6
SPF product formulation
At a formulation level, most modern sunscreens utilise a combination of organic (chemical) filters and inorganic (mineral) filters. Organic filters, such as avobenzone and octocrylene, absorb UV radiation and convert it to heat, whereas inorganic filters, including zinc oxide and titanium dioxide, reflect and scatter UV radiation while also providing some absorption.7 These filters are often combined to optimise photostability, broaden spectral coverage and improve cosmetic acceptability.
In addition to UV filters, formulations frequently include antioxidants and anti-inflammatory agents. These ingredients may mitigate UV-induced oxidative stress and inflammatory cascades that contribute to photoageing and carcinogenesis. Importantly, concerns have been raised that such ingredients could artificially inflate SPF values by suppressing erythema. However, in vivo studies demonstrate that commonly used antioxidant and anti-inflammatory additives do not alter measured SPF values, confirming that labelled SPF reflects true photoprotective capacity.
SPF product limitations
Despite strong evidence for efficacy, the real-world effectiveness of sunscreen is heavily influenced by user behaviour. Adherence is often limited by factors such as texture, greasiness, irritation, white cast and cost. Consumer preference studies demonstrate that individuals are willing to pay approximately £24 per month (converted from US$30.10) for an “ideal” sunscreen, highlighting the importance of formulation aesthetics and accessibility in promoting consistent use.⁷
Additionally, misconceptions regarding sunscreen safety that often proliferate on social media can negatively influence adherence. For instance, research shows that using sunscreen in everyday situations has minimal effect on 25(OH)D levels. Therefore, worries about vitamin D should not override recommendations for skin cancer prevention.8 This underscores the need for clear, evidence-based patient education.
Current SPF guidelines
In the UK, current guidance recommends the use of SPF 30 or higher for daily use, with SPF 50 advised for prolonged or high-intensity UV exposure, alongside adequate UVA protection (for example, a UVA circle logo or PA rating).6
However, achieving the labelled SPF requires correct application. Sunscreen should be applied at a density of approximately 2 mg/cm², equating to around 6–8 teaspoons for full body coverage, 15–20 minutes before sun exposure. Reapplication every two hours, and after swimming, sweating or towel-drying, is essential to maintain protection.6 In practice, most individuals under-apply sunscreen, resulting in significantly lower protection than the labelled SPF. 9
Emerging evidence also highlights the importance of UVA protection in everyday exposure. Repeated low-dose UVA1 exposure, even at levels encountered in daily life, has been shown to induce collagen-degrading matrix metalloproteinases despite visible tanning, reinforcing that a tan does not confer meaningful protection against dermal damage.¹
Sunscreens in skin of colour
Considerations around sunscreen use must also extend to skin of colour. While increased epidermal melanin provides partial photoprotection and reduces the incidence of UV-induced skin cancers, individuals with darker skin tones are not immune to UV damage. Skin cancers in these populations often present at a more advanced stage and may carry worse prognoses due to delayed diagnosis.10 Furthermore, UV exposure plays a significant role in pigmentary disorders, including melasma and post-inflammatory hyperpigmentation, which are highly prevalent and clinically significant in skin of colour. As such, sunscreen remains a critical component of management in all skin types, with tinted formulations offering additional benefits in visible light protection.11
In conclusion, SPF is a robust, clinically validated measure of UVB protection, but optimal photoprotection requires a broader perspective. Effective sun protection depends on broad-spectrum coverage, adequate quantity, correct timing and consistent use. When used appropriately, sunscreen remains one of the most evidence-based interventions available for reducing the risks of skin cancer, photoageing and pigmentary disorders.
Dr Ginni Mansberg
Dr Ginni Mansberg is a GP, TV presenter, podcaster, author and columnist. She is a physician specialising in women’s health, menopause and all things skin. She is also the co-founder and medical director of science-based cosmeceutical skincare brand, ESK.
